No Data
No Data
No Data
No Data
No Data
Acrivon Therapeutics Is Maintained at Outperform by BMO Capital
Acrivon Therapeutics Is Maintained at Outperform by BMO Capital
Dow Jones14:12 ET
Express News | BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25
Benzinga14:01 ET
Buy Rating on Acrivon Therapeutics With Increased Target Price Amid Promising ACR-368 Trial Data
TipRanksApr 26 07:20 ET
Express News | Acrivon Therapeutics Inc : BMO Raises Target Price to $25 From $18
ReutersApr 26 07:01 ET
Acrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market Potential
TipRanksApr 25 12:46 ET
Acrivon Therapeutics Is Maintained at Overweight by Piper Sandler
Acrivon Therapeutics Is Maintained at Overweight by Piper Sandler
Dow JonesApr 25 09:04 ET
Jaguar8 : Twinning!
TrytosaveabitOP Jaguar8: Hehehe!
Jaguar8 : You really caught both similarities. Sharp!
TrytosaveabitOP Jaguar8: They are starting to separate! I would like them twinning again but both up up up! Hehehe
Jaguar8 TrytosaveabitOP: Hahaha they decided to divorce then
No Data
No Data
JESSE JAMES8832 : i expeced so much better for this
JESSE JAMES8832 : maybe fill that gap to 6.62?
TrytosaveabitOP JESSE JAMES8832: Yup! But look at PCSA! It gets just a PT increase and flyin! This gets great news and a PT increase and dud? Hehehe
TrytosaveabitOP JESSE JAMES8832: It might try?